Brind.

The European Commission approved SKYRIZI for pediatric psoriasis treatment.

Steady: 0 in the last 7 days Updated oct 6

The latest in this situation

  1. AbbVie's drug applications are successfully gaining market access in Europe.

How it started

2 reports, 1 independent, last reported Jun 23. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The European Commission approved SKYRIZI for pediatric psoriasis treatment.

Who's involved

What this event is mainly about
AbbVieEuropean Commission

How it developed

Newest first. Tap a step to see who reported it.
  1. A drug application from AbbVie is currently seeking a positive opinion from the CHMP, with the final decision impacting market access in the EU.Sub-event
  2. EC approved SKYRIZI for pediatric psoriasis use.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped